Marktprognose für Pharmakokinetikdienstleistungen in Nordamerika bis 2031 – Regionale Analyse – nach Arzneimitteltyp (kleine Moleküle, große Moleküle und Impfstoffe), Servicetyp (präklinische ADME- und Humanstudien, PK/PD-Analyse und -Berichterstattung, Dosierungssimulationen, Risikoanalyse und andere), therapeutische Anwendung (Onkologie, Infektionskrankheiten, neurologische Erkrankungen, Autoimmunerkrankungen, gynäkologische Erkrankungen, Herz-Kreislauf-Erkrankungen, Atemwegserkrankungen und andere) und Endbenutzer (Pharma- und Biotechnologieunternehmen, Auftragsforschungsinstitute und andere)

BMIRE00030931 | Pages: 87 | Pharmaceuticals | Oct 2024 | Type: Regional | Status: Published
Der nordamerikanische Markt für Pharmakokinetikdienstleistungen wurde im Jahr 2023 auf 375,36 Millionen US-Dollar geschätzt und soll bis 2031 692,77 Millionen US-Dollar erreichen; es wird geschätzt, dass er von 2023 bis 2031 eine durchschnittliche jährliche Wachstumsrate von 8,0 % verzeichnet.

Ausweitung des Anwendungsbereichs pharmakokinetischer Studien treibt den nordamerikanischen Markt für Pharmakokinetikdienstleistungen an

Pharmakokinetische Studien werden eingesetzt, um verschiedene Parameter zu bestimmen, wie z. B. die Höhe der Humanäquivalentdosis (HED), die Höhe ohne beobachtete Wirkung (NOEL) und pharmakokinetische/pharmakodynamische Tests. Der Hauptfokus jedes durchgeführten präklinischen Programms liegt auf der Unterstützung der Analyse eines sicheren und wirksamen Dosierungsbereichs für Tests in pharmakokinetischen Studien. Mehrere toxikologische Studien führten Daten zur NOEL durch, d. h. zur höchsten Dosis, die keine Nebenwirkungen hervorruft. Diese Dosisstufe wird weiter in eine HED-Stufe auf Basis der vergleichenden Körperoberfläche umgerechnet, wenn keine klinischen pharmakokinetischen Daten vorliegen. Das Verständnis des pharmakokinetischen Profils eines potenziellen Arzneimittelkandidaten spielt eine wichtige Rolle im Arzneimittelentdeckungsprogramm. Regulierungsbehörden spielen eine wichtige Rolle bei der Förderung der Durchführung pharmakokinetischer Studien. Diese Studien sind auch von entscheidender Bedeutung für die Optimierung der pharmazeutischen Versorgung von Patienten in Krankenhäusern. Das PK-Modell wird häufig angewendet, um die Exposition gegenüber Arzneimitteln und die Konzentration von Arzneimitteln zu bestimmen, um die optimale Dosierung zu analysieren, und um die Verteilung von Arzneimitteln im menschlichen Körper zu analysieren. Gesundheitsdienstleister setzen die Prinzipien der PK um, um Arzneimittelkonzentrationen und -dosen einiger Arzneimittel zu überwachen, die beabsichtigten therapeutischen Ergebnisse zu maximieren und Toxizitäten zu minimieren.

Marktübersicht für Pharmakokinetikdienstleistungen in Nordamerika

Die USA haben den größten Anteil am nordamerikanischen Markt für Pharmakokinetikdienstleistungen. Das Land hat sich zu einem führenden Standort für klinische Forschung entwickelt; etwa 50 % aller klinischen Studien weltweit werden dort durchgeführt. Die Verfügbarkeit einer etablierten medizinischen Infrastruktur, schnelle Genehmigungsfristen und ein günstiger regulatorischer Rahmen schaffen ein günstiges Umfeld für pharmazeutische Forschungsunternehmen, um klinische Studien durchzuführen. Darüber hinaus werden die in den USA durchgeführten Studien generierten Daten weltweit akzeptiert. Laut einem Bericht der Weltgesundheitsorganisation (WHO) verzeichneten die USA im Jahr 2021 die höchste Anzahl klinischer Studien (157.618).

Umsatz und Prognose des nordamerikanischen Marktes für Pharmakokinetikdienstleistungen bis 2031 (in Mio. USD)

Segmentierung des nordamerikanischen Marktes für Pharmakokinetikdienstleistungen

Der nordamerikanische Markt für Pharmakokinetikdienstleistungen ist nach Arzneimitteltyp, Dienstleistungstyp, therapeutischer Anwendung, Endbenutzer und Land kategorisiert.

Basierend auf dem Arzneimitteltyp ist der nordamerikanische Markt für Pharmakokinetikdienstleistungen in kleine Moleküle, große Moleküle und Impfstoffe segmentiert. Das Segment der kleinen Moleküle hatte 2023 den größten Marktanteil.

Nach Dienstleistungsart ist der nordamerikanische Markt für Pharmakokinetikdienstleistungen in präklinische ADME- und Humanstudien, PK/PD-Analyse und -Berichterstattung, Dosierungssimulationen, Risikoanalysen und andere unterteilt. Das Segment präklinische ADME- und Humanstudien hatte 2023 den größten Marktanteil.

Nach therapeutischer Anwendung ist der nordamerikanische Markt für Pharmakokinetikdienstleistungen in Onkologie, Infektionskrankheiten, neurologische Erkrankungen, Autoimmunerkrankungen, gynäkologische Erkrankungen, Herz-Kreislauf-Erkrankungen, Atemwegserkrankungen und andere unterteilt. Das Segment Onkologie hatte 2023 den größten Marktanteil.

Nach Endbenutzer ist der nordamerikanische Markt für Pharmakokinetikdienstleistungen in Pharma- und Biotechnologieunternehmen, Auftragsforschungsinstitute und andere unterteilt. Das Segment der Auftragsforschungsinstitute hatte 2023 den größten Marktanteil.

Nach Ländern ist der nordamerikanische Markt für Pharmakokinetikdienstleistungen in die USA, Kanada und Mexiko unterteilt. Die USA dominierten 2023 den Marktanteil der nordamerikanischen Pharmakokinetikdienstleistungen.

Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; und SGS SA sind einige der führenden Unternehmen auf dem nordamerikanischen Markt für Pharmakokinetikdienstleistungen.

TABLE OF CONTENTS

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. North America Pharmacokinetics Services Market Landscape

4.1 PEST Analysis

5. North America Pharmacokinetics Services Market - Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of Chronic and Infectious Diseases

5.1.2 Expanding Range of Application of Pharmacokinetic Studies

5.1.3 Outsourcing of Pharmacokinetics Services to CROs

5.2 Market Restraints

5.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries

5.3 Market Opportunities

5.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics

5.4 Future Trend

5.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services

5.5 Impact of Drivers and Restraints:

6. Pharmacokinetics Services Market - North America Analysis

6.1 North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

7. North America Pharmacokinetics Services Market Analysis - by Drug Type

7.1 Overview

7.2 Small Molecule

7.2.1 Overview

7.2.2 Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7.3 Large Molecule

7.3.1 Overview

7.3.2 Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7.4 Vaccines

7.4.1 Overview

7.4.2 Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Pharmacokinetics Services Market Analysis - by Service Type

8.1 Overview

8.2 Pre-Clinical ADME and Human Studies

8.2.1 Overview

8.2.2 Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.3 PK/PD Analysis and Reporting

8.3.1 Overview

8.3.2 PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.4 Dosing Simulations

8.4.1 Overview

8.4.2 Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.5 Risk Analysis

8.5.1 Overview

8.5.2 Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.6 Others

8.6.1 Overview

8.6.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Pharmacokinetics Services Market Analysis - by Therapeutic Application

9.1 Oncology

9.1.1 Overview

9.1.2 Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9.2 Infectious Diseases

9.2.1 Overview

9.2.2 Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9.3 Neurological Disorders

9.3.1 Overview

9.3.2 Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9.4 Autoimmune Diseases

9.4.1 Overview

9.4.2 Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9.5 Gynecological Disorders

9.5.1 Overview

9.5.2 Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9.6 Cardiovascular Diseases

9.6.1 Overview

9.6.2 Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9.7 Respiratory Disorders

9.7.1 Overview

9.7.2 Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9.8 Others

9.8.1 Overview

9.8.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Pharmacokinetics Services Market Analysis - by End User

10.1 Pharmaceutical and Biotechnology Companies

10.1.1 Overview

10.1.2 Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.2 Contract Research Organization

10.2.1 Overview

10.2.2 Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.3 Others

10.3.1 Overview

10.3.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Pharmacokinetics Services Market - Country Analysis

11.1 North America

11.1.1 North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)

11.1.1.1 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

11.1.1.1.1 Overview

11.1.1.1.2 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

11.1.1.1.3 United States: North America Pharmacokinetics Services Market Breakdown, by Drug Type

11.1.1.1.4 United States: North America Pharmacokinetics Services Market Breakdown, by Service Type

11.1.1.1.5 United States: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application

11.1.1.1.6 United States: North America Pharmacokinetics Services Market Breakdown, by End User

11.1.1.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

11.1.1.2.1 Overview

11.1.1.2.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

11.1.1.2.3 Canada: North America Pharmacokinetics Services Market Breakdown, by Drug Type

11.1.1.2.4 Canada: North America Pharmacokinetics Services Market Breakdown, by Service Type

11.1.1.2.5 Canada: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application

11.1.1.2.6 Canada: North America Pharmacokinetics Services Market Breakdown, by End User

11.1.1.3 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

11.1.1.3.1 Overview

11.1.1.3.2 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

11.1.1.3.3 Mexico: North America Pharmacokinetics Services Market Breakdown, by Drug Type

11.1.1.3.4 Mexico: North America Pharmacokinetics Services Market Breakdown, by Service Type

11.1.1.3.5 Mexico: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application

11.1.1.3.6 Mexico: North America Pharmacokinetics Services Market Breakdown, by End User

12. Company Profile

12.1 Charles River Laboratories International Inc

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Eurofins Scientific SE

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 Evotec SE

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 Certara Inc.

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.5 Parexel International Corp

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 Thermo Fisher Scientific Inc.

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

12.7 Allucent

12.7.1 Key Facts

12.7.2 Business Description

12.7.3 Products and Services

12.7.4 Financial Overview

12.7.5 SWOT Analysis

12.7.6 Key Developments

12.8 PACIFIC BIOLABS

12.8.1 Key Facts

12.8.2 Business Description

12.8.3 Products and Services

12.8.4 Financial Overview

12.8.5 SWOT Analysis

12.8.6 Key Developments

12.9 SGS SA

12.9.1 Key Facts

12.9.2 Business Description

12.9.3 Products and Services

12.9.4 Financial Overview

12.9.5 SWOT Analysis

12.9.6 Key Developments

13. Appendix

13.1 About The Insight Partners

13.2 Glossary of Terms for Pharmacokinetic Services Market

 

List of Tables

Table 1. North America Pharmacokinetics Services Market Segmentation

Table 2. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 3. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 4. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 5. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 6. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 7. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 8. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 9. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 10. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 11. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 12. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 13. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 14. Glossary of Terms

 

 

List of Figures

Figure 1. North America Pharmacokinetics Services Market Segmentation, by Country

Figure 2. PEST Analysis

Figure 3. North America Pharmacokinetics Services Market - Key Market Dynamics

Figure 4. Impact Analysis of Drivers and Restraints

Figure 5. North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

Figure 6. North America Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)

Figure 7. Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 8. Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 9. Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 10. North America Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)

Figure 11. Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 12. PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 13. Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 14. Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 15. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 16. North America Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)

Figure 17. Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 18. Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 19. Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 20. Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 21. Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 22. Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 23. Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 24. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 25. North America Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)

Figure 26. Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 27. Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 28. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 29. North America Pharmacokinetics Services Market by Key Countries - Revenue (2023) (US$ Million)

Figure 30. North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)

Figure 31. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 32. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)

Figure 33. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)

  1. Charles River Laboratories International Inc
  2. Eurofins Scientific SE
  3. Evotec SE
  4. Certara Inc.
  5. Parexel International Corp
  6. Thermo Fisher Scientific Inc.
  7. Allucent
  8. PACIFIC BIOLABS
  9. SGS SA
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America pharmacokinetics services market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the North America pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America pharmacokinetics services market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2840
Site License
$4550
$3640
Enterprise License
$5550
$4440